Schrodinger Inc (SDGR)

$18.79 +0.29 (1.57%)
Market Cap 1.32B
Revenue (ttm) 207.54M
Net Income (ttm) -187.12M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -90.16%
Debt to Equity Ratio 0.00
Volume 1,178,200
Avg Vol 941,688
Day's Range N/A - N/A
Shares Out 73.67M
Stochastic %K 62%
Beta 1.54
Analysts Strong Sell
Price Target $27.22

Company Profile

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through...

Industry: Health Information Services
Sector: Healthcare
Phone: 212 295 5800
Address:
1540 Broadway, 24th Floor, New York, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 26 at 5:33 PM
$SDGR RSI: 56.69, MACD: 0.0437 Vol: 0.58, MA20: 17.92, MA50: 18.70 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ConsolidationCore
ConsolidationCore Dec. 25 at 4:36 PM
$SDGR The setup offers potential, but only if discipline accelerates faster than complexity. Management alignment and prioritization play a larger role from here. Failure to deliver would likely trigger renewed valuation compression. Execution precision will determine whether this evolves or stalls.
1 · Reply
beckman07
beckman07 Dec. 25 at 12:46 AM
$SDGR This is ridiculous. 2025 is almost over, and there's been zero news about the research. Zero integrity.
0 · Reply
madnessofcrowds
madnessofcrowds Dec. 24 at 5:45 PM
$SDGR even more, thanks for the discount
0 · Reply
madnessofcrowds
madnessofcrowds Dec. 24 at 5:34 PM
$SDGR bought more
0 · Reply
FrontierFund
FrontierFund Dec. 24 at 10:41 AM
$SDGR Future price discovery depends on how strategic priorities translate into measurable operating outcomes. Long-term optimism depends on disciplined follow-through.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 23 at 2:45 PM
$SDGR RSI: 62.25, MACD: 0.0353 Vol: 0.61, MA20: 17.85, MA50: 18.77 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
CycleTrade
CycleTrade Dec. 23 at 2:39 PM
$SDGR should be good
0 · Reply
madnessofcrowds
madnessofcrowds Dec. 22 at 11:51 PM
$SDGR quadrupled position before the open
0 · Reply
Monkeyy
Monkeyy Dec. 22 at 2:28 PM
$SDGR looks bottomed out
1 · Reply
Latest News on SDGR
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Dec 17, 2025, 8:30 AM EST - 20 days ago

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Unlocking Hidden Value In Schrodinger's Box

Dec 2, 2025, 3:08 PM EST - 5 weeks ago

Unlocking Hidden Value In Schrodinger's Box

Schrödinger to Present at Jefferies London Healthcare Conference

Nov 6, 2025, 8:30 AM EST - 2 months ago

Schrödinger to Present at Jefferies London Healthcare Conference

Schrödinger, Inc. (SDGR) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 10:41 PM EST - 2 months ago

Schrödinger, Inc. (SDGR) Q3 2025 Earnings Call Transcript

Schrödinger Reports Third Quarter 2025 Financial Results

Nov 5, 2025, 4:05 PM EST - 2 months ago

Schrödinger Reports Third Quarter 2025 Financial Results

Copernic Catalysts Announces Achievement of Ammonia Catalyst Milestone in Research Collaboration with Schrödinger

Oct 30, 2025, 7:30 AM EDT - 2 months ago

Copernic Catalysts Announces Achievement of Ammonia Catalyst Milestone in Research Collaboration with Schrödinger

Schrödinger to Announce Third Quarter 2025 Financial Results on November 5

Oct 22, 2025, 8:30 AM EDT - 2 months ago

Schrödinger to Announce Third Quarter 2025 Financial Results on November 5

Schrödinger, Inc. (SDGR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 8, 2025, 3:05 PM EDT - 4 months ago

Schrödinger, Inc. (SDGR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

Aug 27, 2025, 8:30 AM EDT - 4 months ago

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

Schrödinger Announces Discontinuation of SGR-2921 Program

Aug 14, 2025, 7:00 AM EDT - 5 months ago

Schrödinger Announces Discontinuation of SGR-2921 Program

Schrödinger, Inc. (SDGR) Q2 2025 Earnings Call Transcript

Aug 6, 2025, 9:20 PM EDT - 5 months ago

Schrödinger, Inc. (SDGR) Q2 2025 Earnings Call Transcript

Schrödinger Reports Second Quarter 2025 Financial Results

Aug 6, 2025, 4:05 PM EDT - 5 months ago

Schrödinger Reports Second Quarter 2025 Financial Results

Schrödinger to Announce Second Quarter 2025 Financial Results on August 6

Jul 25, 2025, 8:30 AM EDT - 5 months ago

Schrödinger to Announce Second Quarter 2025 Financial Results on August 6

Material Informatics Company Evaluation Report 2025 | Schrodinger, Dassault Systèmes, and Citrine Informatics Drive Market Growth Through AI, Simulation, and Collaboration

Jul 18, 2025, 10:25 AM EDT - 6 months ago

Material Informatics Company Evaluation Report 2025 | Schrodinger, Dassault Systèmes, and Citrine Informatics Drive Market Growth Through AI, Simulation, and Collaboration

Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

Jul 17, 2025, 8:00 AM EDT - 6 months ago

Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

Jun 27, 2025, 8:00 AM EDT - 6 months ago

Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia

Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results

Jun 13, 2025, 1:02 PM EDT - 7 months ago

Schrödinger: Assessing The Signal And The Noise In The Phase 1 Results

Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress

Jun 12, 2025, 7:00 AM EDT - 7 months ago

Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Shareholders to Inquire about Securities Investigation

Jun 6, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Shareholders to Connect

Jun 5, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Shareholders to Reach Out

Jun 4, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Shareholders to Learn More About the Investigation

Jun 3, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Shareholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities Investigation

Jun 2, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Investors to Learn More About the Investigation

Jun 1, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Investors to Learn More About the Investigation

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 30, 2025, 10:00 AM EDT - 7 months ago

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

May 29, 2025, 5:00 PM EDT - 7 months ago

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Investors to Connect

May 29, 2025, 10:00 AM EDT - 7 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Investors to Connect

Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

May 29, 2025, 8:00 AM EDT - 7 months ago

Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

May 28, 2025, 12:22 PM EDT - 7 months ago

Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

AMGN BIIB DHR GILD IBB ILMN NVS

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Stockholders to Reach Out

May 27, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Schrödinger, Inc. (SDGR) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Stockholders to Connect

May 26, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Schrödinger, Inc. (SDGR) And Encourages Stockholders to Connect

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 25, 2025, 10:00 AM EDT - 8 months ago

Schrödinger, Inc. (SDGR) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Stockholders to Learn More About the Investigation

May 23, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Schrödinger, Inc. (SDGR) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Investors to Inquire about Securities Investigation

May 22, 2025, 12:00 PM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Schrödinger, Inc. (SDGR) Investors to Inquire about Securities Investigation

Schrödinger to Present at Jefferies Global Healthcare Conference

May 22, 2025, 8:30 AM EDT - 8 months ago

Schrödinger to Present at Jefferies Global Healthcare Conference

Schrödinger: Regulatory Tailwinds Are Supportive Of Continued Strong Growth (Rating Upgrade)

May 20, 2025, 11:37 PM EDT - 8 months ago

Schrödinger: Regulatory Tailwinds Are Supportive Of Continued Strong Growth (Rating Upgrade)

Schrödinger Announces CFO Appointment

May 20, 2025, 6:30 AM EDT - 8 months ago

Schrödinger Announces CFO Appointment

Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma

May 14, 2025, 9:30 AM EDT - 8 months ago

Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma

Schrödinger, Inc. (SDGR) Q1 2025 Earnings Call Transcript

May 7, 2025, 5:59 PM EDT - 8 months ago

Schrödinger, Inc. (SDGR) Q1 2025 Earnings Call Transcript

Schrödinger Reports Strong First Quarter 2025 Financial Results

May 7, 2025, 4:05 PM EDT - 8 months ago

Schrödinger Reports Strong First Quarter 2025 Financial Results

Schrödinger to Present at BofA Securities 2025 Healthcare Conference

May 5, 2025, 8:30 AM EDT - 8 months ago

Schrödinger to Present at BofA Securities 2025 Healthcare Conference

Schrödinger Presents New Preclinical Data at AACR Annual Meeting

Apr 28, 2025, 8:00 AM EDT - 9 months ago

Schrödinger Presents New Preclinical Data at AACR Annual Meeting

Schrödinger to Announce First Quarter 2025 Financial Results on May 7

Apr 23, 2025, 8:30 AM EDT - 9 months ago

Schrödinger to Announce First Quarter 2025 Financial Results on May 7

Schrödinger's Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

Apr 14, 2025, 8:00 AM EDT - 9 months ago

Schrödinger's Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs

Schrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade)

Apr 12, 2025, 10:26 AM EDT - 9 months ago

Schrödinger Poised For Growth As FDA Shifts Away From Animal Testing (Upgrade)

Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

Mar 10, 2025, 8:30 AM EDT - 10 months ago

Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 26 at 5:33 PM
$SDGR RSI: 56.69, MACD: 0.0437 Vol: 0.58, MA20: 17.92, MA50: 18.70 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
ConsolidationCore
ConsolidationCore Dec. 25 at 4:36 PM
$SDGR The setup offers potential, but only if discipline accelerates faster than complexity. Management alignment and prioritization play a larger role from here. Failure to deliver would likely trigger renewed valuation compression. Execution precision will determine whether this evolves or stalls.
1 · Reply
beckman07
beckman07 Dec. 25 at 12:46 AM
$SDGR This is ridiculous. 2025 is almost over, and there's been zero news about the research. Zero integrity.
0 · Reply
madnessofcrowds
madnessofcrowds Dec. 24 at 5:45 PM
$SDGR even more, thanks for the discount
0 · Reply
madnessofcrowds
madnessofcrowds Dec. 24 at 5:34 PM
$SDGR bought more
0 · Reply
FrontierFund
FrontierFund Dec. 24 at 10:41 AM
$SDGR Future price discovery depends on how strategic priorities translate into measurable operating outcomes. Long-term optimism depends on disciplined follow-through.
1 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Dec. 23 at 2:45 PM
$SDGR RSI: 62.25, MACD: 0.0353 Vol: 0.61, MA20: 17.85, MA50: 18.77 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
CycleTrade
CycleTrade Dec. 23 at 2:39 PM
$SDGR should be good
0 · Reply
madnessofcrowds
madnessofcrowds Dec. 22 at 11:51 PM
$SDGR quadrupled position before the open
0 · Reply
Monkeyy
Monkeyy Dec. 22 at 2:28 PM
$SDGR looks bottomed out
1 · Reply
madnessofcrowds
madnessofcrowds Dec. 19 at 11:40 AM
$SDGR bought 1K shares
0 · Reply
Jasooon
Jasooon Dec. 18 at 12:57 AM
$SDGR
0 · Reply
Jasooon
Jasooon Dec. 18 at 12:56 AM
$SDGR
0 · Reply
JarvisFlow
JarvisFlow Dec. 15 at 11:48 AM
B of A Securities has updated their rating for Schrodinger ( $SDGR ) to Buy with a price target of 24.
1 · Reply
TACP
TACP Dec. 12 at 5:46 PM
$SDGR BTO Jan 16 $20C. My PTs: $18.83, 19.35, and $19.85
0 · Reply
scott52
scott52 Dec. 12 at 1:34 AM
$SDGR My son just sent this to me. It's an entry in the Urban Dictionary: Schrodinger's Douchebag: a guy who says offensive things and decides whether he was joking based on the reaction of the people around him. I think that's pretty good. But from my perspective, Ramy will always be Schrodinger's Douchebag. Just saying.
0 · Reply
shrwd
shrwd Dec. 11 at 7:15 PM
$SDGR
0 · Reply
Weber10
Weber10 Dec. 10 at 8:15 PM
$SDGR Fed cut rates by 75 basis points this year and this is supposed to be good for the biotech sector... yet our stock price sits in the toilet. Here's to hoping we are involved in the Genesis Mission Executive Order signed in November which along with phasing out animal testing announced earlier this year are major tailwinds for this company specifically... yeah I know I'm pulling straws but this stock has been stuck in purgatory for too long... maybe a new dawn is on the horizon for 2026... sometimes you have to dream when the reality here has been a fukkin nightmare thus far.
1 · Reply
scott52
scott52 Dec. 5 at 2:55 PM
$SDGR MS just lowered its PT to $18. There may be a reason to own this stock, but I honestly don't see it. My money is going elsewhere for now. I've cut my position by 70%. I'm keeping a rooting interest. But there are no catalysts until mid 2026.
2 · Reply
BearishCandle
BearishCandle Dec. 5 at 3:22 AM
$SDGR headed to 20
0 · Reply
Jasooon
Jasooon Nov. 26 at 3:14 AM
$TEM $SDGR great for drug discovery. The EO should be a great macro tailwind for them.
0 · Reply
Jasooon
Jasooon Nov. 25 at 3:05 AM
$SDGR hmmm, wonder who this could benefit? Wouldn’t it be great if there was a proven software platform to use to help out with this? Anyone know a good company?
1 · Reply